Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.58 |
| ▸ | ERBB2 | P04626 | 10/20 | 0.58 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 2/20 | 0.42 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.42 |
| ▸ | FYN | P06241 | 2/20 | 0.42 |
| ▸ | SRC | P12931 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7125474 | 0.91 | EGFR (0.60) | EGFRERBB2KDRJAK3ERBB4 | |
| SCHEMBL7128994 | 0.90 | EGFR (0.60) | EGFRERBB2KDRJAK3ERBB4 | |
| SCHEMBL7120527 | 0.90 | EGFR (0.59) | EGFRERBB2JAK3ERBB4 | |
| SCHEMBL7119065 | 0.84 | EGFR (0.54) | EGFRERBB2FYNSRC | |
| SCHEMBL7127206 | 0.81 | EGFR (0.50) | EGFRERBB2ERBB4FYNSRC | |
| SCHEMBL7128989 | 0.81 | EGFR (0.62) | EGFRERBB2KDRJAK3ERBB4 | |
| SCHEMBL7120519 | 0.81 | EGFR (0.61) | EGFRERBB2JAK3ERBB4 | |
| SCHEMBL7129025 | 0.78 | EGFR (0.66) | EGFRERBB2JAK3ERBB4 | |
| SCHEMBL7129023 | 0.78 | EGFR (0.66) | EGFRERBB2JAK3ERBB4 | |
| SCHEMBL7243135 | 0.78 | EGFR (0.69) | EGFRERBB2JAK3ERBB4FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030087881-A1 | Irreversible inhibitors of tyrosine kinases | BRIDGES ALEXANDER JAMES (US) | 2003-05-08 | — | — | US | claimed |
| US-6153617-A | Irreversible bicyclic inhibitors of tyrosine kinases | WARNER-LAMBERT COMPANY (US) | 2000-11-28 | — | — | US | claimed |
| WO-1999006396-A1 | IRREVERSIBLE BICYCLIC INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1999-02-11 | — | — | WO | claimed |
| US-20030087881-A1 | Irreversible inhibitors of tyrosine kinases | BRIDGES ALEXANDER JAMES (US) | 2003-05-08 | — | — | US | disclosed |
| US-6153617-A | Irreversible bicyclic inhibitors of tyrosine kinases | WARNER-LAMBERT COMPANY (US) | 2000-11-28 | — | — | US | disclosed |
| WO-1999006396-A1 | IRREVERSIBLE BICYCLIC INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087881-A1 | Irreversible inhibitors of tyrosine kinases | ERBB2, ERBB3, LCK | EGFR 26/4885ERBB2 1/4885KDR 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.